Abnormal Sleep Behaviours Across the Spectrum of Alzheimer’s Disease Severity: Influence of APOE Genotypes and Lewy Bodies

Author(s): Ka Yi G. Koo, Tom A. Schweizer, Corinne E. Fischer, David G. Munoz*.

Journal Name: Current Alzheimer Research

Volume 16 , Issue 3 , 2019

  Journal Home
Translate in Chinese
Submit Manuscript
Submit Proposal

Abstract:

Background: The Apolipoprotein (APOE) ε4 allele is a well-known risk factor for Alzheimer’s Disease (AD), and sleep disturbances are commonly associated with AD. However, few studies have investigated the relationship between APOE ε4 and abnormal sleep patterns (N+) in AD.

Objective: To examine the relationship between APOE genotype, Lewy body pathology, and abnormal sleep patterns in a large group of subjects with known AD load evaluated upon autopsy.

Method: Data from 2,368 cases obtained from the National Alzheimer’s Coordinating Centre database were categorized as follows: Braak Stage V/VI and CERAD frequent neuritic plaques as high load AD, Braak Stage III/IV and moderate CERAD as intermediate load AD, and Braak Stage 0/I/II and infrequent CERAD as no to low load AD. Cases discrepant between the two measures were discarded.

Results: Disrupted sleep was more frequent in males (42.4%) compared to females (35.1%), and in carriers (42.3%) as opposed to non-carriers (36.5%) of ε4. Amongst female subjects with high AD load and Lewy body pathology, homozygous (ε4/ε4) carriers experienced disrupted sleep more often compared with heterozygous (ε4/x) or non-carriers of ε4. Such recessive, gender-specific, and Lewy body association is reminiscent of the ε4 effect on psychosis in AD. However, such association was lost after adjusting for covariates. In subjects with no to low AD pathology, female ε4 carriers had significantly more nighttime disturbances than non-carriers; this effect is independent of the presence of Lewy body pathology.

Conclusion: The influence of APOE ε4 on sleep disturbances is dependent on gender and severity of AD load.

Keywords: Alzheimer's Disease, apolipoprotein E, sleep behaviours, Lewy bodies, risk factors, neuropathology, gender.

[1]
Kim J, Basak JM, Holtzman DM. The role of apolipoprotein E in Alzheimer’s disease. Neuron 63(3): 287-03. (2009)
[2]
Corder EH, Saunders AM, Strittmatter WJ, Schmechel DE, Gaskell PC, Small GW, et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer’s disease in late onset families. Science 261(5123): 921-3. (1993)
[3]
Farrer LA, Cupples LA, Haines JL, Hyman B, Kukull WA, Mayeux R, et al. Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer Disease Meta Analysis Consortium. JAMA 278(16): 1349-56. (1997)
[4]
Uchikado H, Lin WL, DeLucia MW, Dickson DW. Alzheimer disease with amygdala Lewy bodies: a distinct form of alpha-synucleinopathy. J Neuropathol Exp Neurol 65(7): 685-97. (2006)
[5]
Kotzbauer PT, Trojanowsk JQ, Lee VM. Lewy body pathology in Alzheimer’s disease. J Mol Neurosci 17(2): 225-32. (2001)
[6]
Hamilton RL. Lewy bodies in Alzheimer’s disease: a neuropathological review of 145 cases using alpha-synuclein immunohistochemistry. Brain Pathol 10(3): 378-84. (2000)
[7]
Chung EJ, Babulal GM, Monsell SE, Cairns NJ, Roe CM, Morris JC. Clinical features of alzheimer disease with and without lewy bodies. JAMA Neurol 72(7): 789-96. (2015)
[8]
Lim A, Yu L, Kowgier M, Schneider J, Buchman A, Bennett D. Modification of the relationship of the apolipoprotein e ε4 allele to the risk of alzheimer disease and neurofibrillary tangle density by sleep. JAMA Neurology 70(12): 1544. (2013)
[9]
Vitiello MV, Borson S. Sleep disturbances in patients with Alzheimer’s disease: epidemiology, pathophysiology and treatment. CNS Drugs 15(10): 777-96. (2001)
[10]
Chen DW, Wang J, Zhang LL, Wang YJ, Gao CY. Cerebrospinal fluid amyloid-β levels are increased in patients with insomnia. J Alzheimers Dis 61(2): 645-51. (2018)
[11]
Carvalho DZ, St Louis EK, Knopman DS, Boeve BF, Lowe VF, Roberts RO, et al. Association of excessive daytime sleepiness with longitudinal β-amyloid accumulation in elderly persons without dementia. JAMA Neurol 75(6): 672-80. (2018)
[12]
Sprecher KE, Koscik RL, Carlsson CM, Zetterberg H, Blennow K, Okonkwo OC, et al. Poor sleep is associated with CSF biomarkers of amyloid pathology in cognitively normal adults. Neurology 89(5): 445-53. (2017)
[13]
Ju YE, Lucey BP, Holtzman DM. Sleep and Alzheimer disease pathology--a bidirectional relationship. Nat Rev Neurol 10(2): 115-9. (2013)
[14]
Farlow MR. Alzheimer’s disease: clinical implications of the apolipoprotein E genotype. Neurology 48(5)(Suppl. 6): S30-4. (1997)
[15]
Hostage CA, Roy Choudhury K, Doraiswamy PM, Petrella JR. Alzheimer’s Disease Neuroimaging I. Dissecting the gene dose-effects of the APOE epsilon4 and epsilon2 alleles on hippocampal volumes in aging and Alzheimer’s disease. PLoS One 8(2): e54483. (2013)
[16]
Spira AP, An Y, Resnick SM. Self-reported sleep and beta-amyloid deposition in older adults-reply. JAMA Neurol 71(5): 651-2. (2014)
[17]
Drogos LL, Gill SJ, Tyndall AV, Raneri JK, Parboosingh JS, Naef A, et al. Evidence of association between sleep quality and APOE epsilon4 in healthy older adults: apilot study. Neurology 87(17): 1836-42. (2016)
[18]
Kim J, Fischer CE, Schweizer TA, Munoz DG. Gender and pathology-specific effect of apolipoprotein e genotype on psychosis in Alzheimer’s disease. Curr Alzheimer Res 14(8): 834-40. (2017)
[19]
Payami H, Zareparsi S, Montee KR, Sexton GJ, Kaye JA, Bird TD, et al. Gender difference in apolipoprotein E-associated risk for familial Alzheimer disease: a possible clue to the higher incidence of Alzheimer disease in women. Am J Hum Genet 58(4): 803-11. (1996)
[20]
Altmann A, Tian L, Henderson VW, Greicius MD. Alzheimer’s Disease Neuroimaging Initiative I. Sex modifies the APOE-related risk of developing Alzheimer disease. Ann Neurol 75(4): 563-73. (2014)
[21]
Xing Y, Tang Y, Jia J. Sex differences in neuropsychiatric symptoms of Alzheimer’s disease: the modifying effect of apolipoprotein e epsilon4 status. Behav Neurol 2015: 275256. (2015)
[22]
Stern Y, Jacobs D, Goldman J, Gomez-Tortosa E, Hyman BT, Liu Y, et al. An investigation of clinical correlates of Lewy bodies in autopsy-proven Alzheimer disease. Arch Neurol 58(3): 460-5. (2001)
[23]
Yesavage JA, Friedman L, Kraemer H, Tinklenberg JR, Salehi A, Noda A, et al. Sleep/wake disruption in Alzheimer’s disease: APOE status and longitudinal course. J Geriatr Psychiatry Neurol 17(1): 20-4. (2004)
[24]
Deschenes CL, McCurry SM. Current treatments for sleep disturbances in individuals with dementia. Curr Psychiatry Rep 11(1): 20-6. (2009)
[25]
Bombois S, Derambure P, Pasquier F, Monaca C. Sleep disorders in aging and dementia. J Nutr Health Aging 14(3): 212-7. (2010)
[26]
Wu YH, Swaab DF. Disturbance and strategies for reactivation of the circadian rhythm system in aging and Alzheimer’s disease. Sleep Med 8(6): 623-36. (2007)


Rights & PermissionsPrintExport Cite as


Article Details

VOLUME: 16
ISSUE: 3
Year: 2019
Page: [243 - 250]
Pages: 8
DOI: 10.2174/1567205016666190103161034
Price: $58

Article Metrics

PDF: 28
HTML: 6
EPUB: 1